1. Home
  2. HMN vs PHVS Comparison

HMN vs PHVS Comparison

Compare HMN & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Horace Mann Educators Corporation

HMN

Horace Mann Educators Corporation

HOLD

Current Price

$43.17

Market Cap

1.8B

Sector

Finance

ML Signal

HOLD

Logo Pharvaris N.V.

PHVS

Pharvaris N.V.

HOLD

Current Price

$26.09

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HMN
PHVS
Founded
1945
2015
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Property-Casualty Insurers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
1.7B
IPO Year
1991
2021

Fundamental Metrics

Financial Performance
Metric
HMN
PHVS
Price
$43.17
$26.09
Analyst Decision
Buy
Buy
Analyst Count
5
9
Target Price
$46.75
$39.44
AVG Volume (30 Days)
260.0K
174.2K
Earning Date
02-03-2026
11-12-2025
Dividend Yield
3.24%
N/A
EPS Growth
57.26
N/A
EPS
3.90
N/A
Revenue
$1,701,400,000.00
N/A
Revenue This Year
$7.50
N/A
Revenue Next Year
$2.84
N/A
P/E Ratio
$11.07
N/A
Revenue Growth
6.66
N/A
52 Week Low
$38.76
$11.51
52 Week High
$48.33
$29.80

Technical Indicators

Market Signals
Indicator
HMN
PHVS
Relative Strength Index (RSI) 53.48 47.00
Support Level $42.03 $24.92
Resistance Level $45.13 $28.79
Average True Range (ATR) 1.09 1.46
MACD 0.23 -0.22
Stochastic Oscillator 77.16 24.90

Price Performance

Historical Comparison
HMN
PHVS

About HMN Horace Mann Educators Corporation

Horace Mann Educators Corp is a diversified insurance holding company that markets and underwrites personal lines of property and casualty insurance, retirement annuities, and life insurance. The company's property and casualty operations focus on automobile and homeowner insurance, while the retirement annuities are 403(b) tax-qualified products. Horace Mann Educators markets its products to kindergarten through 12th-grade teachers, administrators, and other employees of public schools and their families. The Company conducts and manages its business in four reporting segments: (1) Property & Casualty, (2) Life & Retirement, (3) Supplemental & Group Benefits and (4) Corporate & Other.

About PHVS Pharvaris N.V.

Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.

Share on Social Networks: